| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [2] |
Siegel RL. Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016. 66(1): 7-30.
|
| [3] |
Gonzalez-Angulo AM, Morales-Vasquez F. Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer[J]. Adv Exp Med Biol, 2007, 608: 1-22.
|
| [4] |
Gennari A, Stockler M, Puntoni M. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials[J]. J Clin Oncol, 2011, 29(16): 2144-2149.
|
| [5] |
Gennari A, D'amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review[J]. Ther Adv Med Oncol, 2011, 3(5): 229-232.
|
| [6] |
Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies[J]. N Engl J Med, 1987, 317(24): 1490-1495.
|
| [7] |
Muss HB, Case LD, Richards F 2nd, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association[J]. N Engl J Med, 1991, 325(19): 1342-1348.
|
| [8] |
Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment[J]. J Clin Oncol, 1998, 16(5): 1669-1676.
|
| [9] |
Nooij MA, de Haes JC. Beex LV, et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences[J]. Eur J Cancer, 2003, 39(5): 614-621.
|
| [10] |
Ejlertsen B, Pfeiffer P, Pedersen D. et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months[J]. Eur J Cancer, 1993, 29A(4): 527-531.
|
| [11] |
French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment[J]. J Clin Oncol, 2000, 18(17): 3115-3124.
|
| [12] |
Becher R, Kloke O, Hayungs J, et al. Epirubicin and ifosfamide in metastatic breast cancer[J]. Semin Oncol, 1996, 23 (3 Suppl 7): 28-33.
|
| [13] |
Park YH, Jung KH. Im SA, et al. PhaseⅢ, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02[J]. J Clin Oncol，2013, 31 (14): 1732-1739.
|
| [14] |
Cinieri S. Chan A, Altundag K, et al. Final results of the randomized phaseⅡ NorCap-CA223 trial comparing first-line all- oral versus taxane-based chemotherapy for HER2-negative metastatic breast cancer[J]. Clin Breast Cancer, 2017, 17(2): 91-99.
|
| [15] |
Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer[J]. J Clin Oncol, 2006, 24(24): 3912-3918.
|
| [16] |
Alba E, Ruiz-Borrego M, Margeli M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study[J]. Breast Cancer Res Treat, 2010, 122(1): 169-176.
|
| [17] |
Wang J, Xu B, Yuan P. et al. Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial[J]. Cancer, 2015, 121(19): 3412-3421.
|
| [18] |
Dong G, Jia Y. Wang X, et al. The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer[J]. Int J Clin Exp Med, 2015. 8 (5): 8283-8287.
|
| [19] |
Liang X, Di L, Song G, et al. Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple- negative breast cancer[J]. Chin J Cancer Res, 2014, 26(5): 550-557.
|
| [20] |
Lv H, Yan M, Zhang M, et al. Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer[J]. Chin J Cancer Res, 2014, 26(6): 692-697.
|
| [21] |
Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12 (11): 631-644.
|
| [22] |
Colleoni M, Rocca A. Sandri MT. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels[J]. Ann Oncol, 2002, 13(1): 73-80.
|
| [23] |
Cancello G, Bagnardi V, Sangalli C, et al. Phase n study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer[J]. Clin Breast Cancer. 2015. 15(4): 259-265.
|
| [24] |
Stockler MR. Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer[J]. J Clin Oncol, 2011, 29(34): 4498-4504.
|
| [25] |
De Iuliis F, Salemo G, Taglieri L, et al. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer[J]. Tumori, 2015, 101(1): 30-35.
|
| [26] |
Cazzaniga ME, Torri V, Riva F, et al. Efficacy and safety of vinorelbine-capecitabine oraL metronomic combination in elderly metastatic breast cancer patients : VICTOR-1 study[J]. Tumori, 2017, 103(1): e4-4e8.
|
| [27] |
Xu B, Ma F. Capecitabine maintenance therapy following capecitabine combined with docetaxel in treatment of metastatic breast cancer (camellia)[R]. Chicago: American Society of Clinical Oncology (ASCO) Annual Meeting, 2015: 146306.
|
| [28] |
Marty M, Cognetti F, Maraninchi D. et al. Randomized phaseⅡ triaL of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23 (19): 4265-4274.
|
| [29] |
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015, 372(8): 724-734.
|
| [30] |
Brufsky A, Lembersky B, Schiffman K, et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer[J]. Clin Breast Cancer, 2005, 6(3): 247-252.
|
| [31] |
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TAnDEM study[J]. J Clin Oncol, 2009, 27(33): 5529-5537.
|
| [32] |
Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol, 2009, 27(33): 5538-5546.
|
| [33] |
Rimawi M, Ferrero JM, Haba-Rodriguez Jdl, et al. Primary analysis of pertain: a randomized, two-arm, open-label, multicenter phase ii trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with her2-positive and hormone receptor-positive metastatic or locally advance breast cancer[R]. San Antonio: San Antonio Breast Cancer Symposium (SABCS), 2016: S3-4.
|
| [34] |
Gradishar WJ, Hegg R, Im SA, et al. Phase 3 study of lapatinib plus trastuzumab and aromatase inhibitor vs tras + AI vs lap + AI in postmenopausal women with her2 +/hr + metastatic breast cancer[R]. Altemative ASCO annual meeting, 2017: 1004.
|
| [35] |
Rossari JR, Metzger-Filho O, Paesmans M. et al. Bevacizumab and breast cancer: a Meta-analysis of first-line phase Ⅲ studies and a critical reappraisal of available evidence[J]. J Oncol, 2012, 2012: 417673.
|
| [36] |
Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(12): 1351-1360.
|
| [37] |
Rossi S, Schinzari G, Basso M, et al. Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review[J]. Future Oncol, 2016, 12(10): 1299-1307.
|
| [38] |
Wang S. Fulvestrant as maintenance therapy after first-line chemotherapy in patients with hormone receptor-positive, her2- negative advanced breast cancer (fancy), a prospective, multicenter, single arm phase 2 study[J]. J Clin Oncol, 2017, 35(48 s): 1066.
|
| [39] |
Cazzaniga ME, Dionisio MR, Riva F. Metronomic chemotherapy for advanced breast cancer patients[J]. Cancer Lett, 2017, 400: 252-258.
|